Topamax and Optic atrophy - a phase IV clinical study of FDA data

Summary:

Optic atrophy is reported as a side effect among people who take Topamax (topiramate), especially for people who are male, 30-39 old, have been taking the drug for 2 - 5 years also take Cymbalta, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Optic atrophy when taking Topamax. It is created by eHealthMe based on reports of 54,158 people who have side effects when taking Topamax from the FDA, and is updated regularly.

What is Topamax?

Topamax has active ingredients of topiramate. It is often used in migraine. eHealthMe is studying from 58,954 Topamax users. Check the latest studies of Topamax.

What is Optic atrophy?

Optic atrophy (the loss of a proportion of optic disc nerve fibres) is found to be associated with 249 drugs and 453 conditions by eHealthMe. Check the latest studies of Optic atrophy.

On Jul, 27, 2026

54,158 people reported to have side effects when taking Topamax.
Among them, 25 people (0.05%) have Optic atrophy.

Among these 25 people:

How long have people been on Topamax when they have Optic atrophy? *

What is the gender of people who have Optic atrophy when taking Topamax? *

female: 14.29 %
male: 85.71 %

What is the age of people who have Optic atrophy when taking Topamax? *

What are other drugs people take besides Topamax? *

What are other side effects people have besides Optic atrophy? *

Visual Field Defect: 12 people, 48.00%
Maculopathy (a condition or disease of the macula, the small spot in the retina where vision is keenest): 10 people, 40.00%
Visual Acuity Reduced (reduced clearness of vision): 7 people, 28.00%
Vision Blurred: 5 people, 20.00%
Color Blindness (inability to view some colour): 5 people, 20.00%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 5 people, 20.00%
Accommodation Disorder: 4 people, 16.00%
Photophobia (extreme sensitivity to light): 4 people, 16.00%
Activities Of Daily Living Impaired: 4 people, 16.00%
Road Traffic Accident: 4 people, 16.00%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 8.00%
Simple Partial Seizures (seizures which affect only a small region of the brain): 1 person, 4.00%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 1 person, 4.00%
Headache (pain in head): 1 person, 4.00%
Grand Mal Convulsion (a type of generalized seizure that affects the entire brain): 1 person, 4.00%
Complex Partial Seizures (epileptic seizure): 1 person, 4.00%
Astrocytoma (tumour of the brain that originate in a particular kind of glial-cells): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Topamax and have Optic atrophy?

- Check whether Optic atrophy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Topamax:

Topamax (58,954 reports)

Optic atrophy treatments and more:

Optic atrophy (2,242 reports)

Browse all side effects of Topamax:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Optic atrophy:

Optic atrophy (249 drugs)

Browse all the conditions that are associated with Optic atrophy:

Optic atrophy (453 conditions)

Related publications that referenced our studies

Baloch M, Siddiqui MA, "Topiramate induced sudden loss of vision", JPMA, 2012 Oct .
Kocamaz, M., & Karadag, O., "Topiramate-Induced Acute Myopia, Diplopia, and Photosensitivity: A Case Report", Beyoglu Eye Journal, 2019 Jan .
Baloch M, Siddiqui MA, "Topiramate induced sudden loss of vision", JPMA, 2012 Oct .
Kocamaz, M., & Karadag, O., "Topiramate-Induced Acute Myopia, Diplopia, and Photosensitivity: A Case Report", Beyoglu Eye Journal, 2019 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on topiramate (the active ingredients of Topamax) and Topamax (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.